Economic burden of selected adverse events in patients aged 65 years with metastatic renal cell carcinoma

Journal of Medical Economics

Volumn 16, Issue 11, 2013, Pages 1300-1306

  Hagiwara, May ^a   Hackshaw, Michelle D ^b   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Adverse event; Economic burden; Metastatic renal cell carcinoma; SEER Medicare database

Indexed keywords

BEVACIZUMAB; PAZOPANIB; SORAFENIB; SUNITINIB;

ABDOMINAL PAIN; AGED; ARTICLE; ASTHENIA; BACKACHE; DIARRHEA; DYSPNEA; FATIGUE; FEMALE; GERIATRIC PATIENT; HAND FOOT SYNDROME; HEALTH CARE COST; HUMAN; HYPERTENSION; ICD-9-CM; KIDNEY METASTASIS; LIMB PAIN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICARE; NAUSEA; NEUTROPENIA; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; TOXICITY; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; KIDNEY NEOPLASMS; MALE; MEDICARE; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SEER PROGRAM; UNITED STATES;

EID: 84886434138     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.838570     Document Type: Article

References (16)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
2. American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society 2012. http://www.cancer.org/acs/groups/con tent/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed November 2012
3. SEER Program Public Use Tapes 1973-2002, November 2004 Submission. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Science, Surveillance Research Program, Cancer Statistics Branch, 2005
4. American Cancer Society. Kidney Cancer (Adult)-Renal Cell Carcinoma. Atlanta, GA: American Cancer Society, 2013. http://www.cancer.org/acs/groups/ cid/documents/webcontent/003052-pdf.pdf. Accessed July, 2013
5. Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34:193-205
6. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75
7. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17
8. Chowdhury S, Larkin JM, Gore ME. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 2008;44:2152-61
9. Highlights of prescribing information: Avastin (bevacizumab), Solution for intravenous infusion. Genentech, Inc., 2011. http://www.gene.com/gene/ products/information/pdf/avastin-prescribing.pdf. Accessed April, 2011
10. Highlights of prescribing information: Nexavar (sorafenib) tablets, oral. Bayer Healthcare Pharmaceuticals Inc., 2011. http://www.univgraph.com/bayer/ inserts/nexavar.pdf. Accessed April, 2011
11. Highlights of prescribing information: Sutent (sunitinib malate) capsules, oral. Pfizer Inc., 2010. http://labeling.pfizer.com/ShowLabeling.aspx? id=607. Accessed April, 2011
12. Highlights of prescribing information: Votrient (pazopanib) tablets. GlaxoSmithKline, 2009. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 0224651 bl.pdf. Accessed April, 2011
13. National Cancer Institute. SEER Surveillance, Epidemiology, and End Results Program. NIH Publication No. 05-4772. September 2005. http://seer.cancer, gov/about/. Accessed October, 2011
14. Choueiri TK, McDermott D, Sheng Duh M, et al. Costs associated with angio-genesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. J Urol Oncol 2012;30:848-55
15. Feinberg BA, Jolly P, Wang ST, et al. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol 2012;29:786-94
16. Mickisch G, Gore M, Escudier B, et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon-a2a compared with sunitinib. Br J Cancer 2010;102:80-6